Status:
ENROLLING_BY_INVITATION
Thromboembolic And Bleeding Risks During anticoaGulant trEatment in Asian paTients With Atrial Fibrillation (TARGET-AF)
Lead Sponsor:
Chung-Ang University Hosptial, Chung-Ang University College of Medicine
Collaborating Sponsors:
Chung-Ang University Gwangmyeong Hospital
Samsung Medical Center
Conditions:
Fibrillation, Atrial
Eligibility:
All Genders
18+ years
Brief Summary
This study was design to investigate the efficacy and safety of NOAC therapy in Koreans
Detailed Description
East Asians have demonstrated a higher bleeding tendency compared to Western populations during an anticoagulation. Consequently, East Asians have been prescribed as a relatively weaker treatment regi...
Eligibility Criteria
Inclusion
- Patients with documented AF on 12-lead ECG, Holter monitoring, or single-lead ECG recordings are eligible for enrollment.
- Based on AF treatment Korean guideline 19, AF patients who require NOAC treatment or are currently on NOAC treatment (within the past 3 months)
- Adults aged 18 or above who have provided consent for clinical information
Exclusion
- Patients with moderate or severe mitral stenosis or mechanical prosthetic valve
Key Trial Info
Start Date :
May 25 2022
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
August 30 2026
Estimated Enrollment :
1021 Patients enrolled
Trial Details
Trial ID
NCT06874894
Start Date
May 25 2022
End Date
August 30 2026
Last Update
December 29 2025
Active Locations (2)
Enter a location and click search to find clinical trials sorted by distance.
1
Chung-Ang University Gwangmyeong Hospital
Gwangmyeong, South Korea
2
Chung-Ang University Hospital
Seoul, South Korea, 06973